Background: Signal transducer and activator of transcription 3 (STAT3) is a member of the cytoplasmic inducible transcription factors and plays an important role in mediating signals from cytokines, chemokines, and growth factors. We and others have found that STAT3 directly regulates pro-fibrotic signaling in the kidney. The STAT3 protein–protein interaction plays an important role in activating its transcriptional activity. It is necessary to identify these interactions to investigate their function in kidney disease. Here, we investigated the protein–protein interaction among three species to find crucial interactions that can be targeted to alleviate kidney disease. Method: In this study, we examined common protein–protein interactions leading to the activation or downregulation of STAT3 among three different species: humans (Homo sapiens), mice (Mus musculus), and rabbits (Oryctolagus cuniculus). Further, we chose to investigate the P300 and STAT3 interaction and performed studies of the activation of STAT3 using IL-6 and inhibition of the P300 by its specific inhibitor A-485 in pericytes. Next, we performed immunoprecipitation to confirm whether A-485 inhibits the binding of P300 to STAT3. Results: Using the STRING application from ExPASy, we found that six proteins, including PIAS3, JAK1, JAK2, EGFR, SRC, and EP300, showed highly confident interactions with STAT3 in humans, mice, and rabbits. We also found that IL-6 treatment increased the acetylation of STAT3 and increased histone 3 lysine acetylation (H3K27ac). Furthermore, we found that the disruption of STAT3 and P300 interaction by the P300 inhibitor A-485 decreased STAT3 acetylation and H3K27ac. Finally, we confirmed that the P300 inhibitor A-485 inhibited the binding of STAT3 with P300, which inhibited its transcriptional activity by reducing the expression of Ccnd1 (Cyclin D1). Conclusions: Targeting the P300 protein interaction with STAT3 may alleviate STAT3-mediated fibrotic signaling in humans and other species.
APOL1-associated renal disease, also known as APOL1 renal risk variants or APOL1 nephropathy, represents a genetic kidney disorder associated with certain variants of the APOL1 gene. The APOL1 gene encodes a protein that plays a crucial role in the immune system’s response to trypanosome infection, the cause of African sleeping sickness. However, two distinct genetic variants of the APOL1 gene, known as G1 and G2, have been conclusively associated with an elevated risk of renal disease in individuals of African descent. Recent research has demonstrated that carrying two copies of either the G1 or G2 variant significantly increases the risk of progressive kidney diseases, such as focal segmental glomerulosclerosis (FSGS) and hypertensive kidney disease. APOL1-associated kidney disease typically presents with features of chronic kidney disease, including proteinuria, hematuria, hypertension, and declining kidney function. Furthermore, hypertension and diabetes serve as additional risk factors for kidney disease, and individuals with both conditions and APOL1 gene variants may further elevate their risk of developing renal disorders. Obesity and smoking also contribute to the risk of kidney disease, particularly in cases with APOL1 gene variants. Moreover, various medical conditions, including lupus, HIV, and sickle cell disease, can exacerbate the likelihood of kidney disease in individuals with APOL1 gene variants. These conditions could lead to end-stage renal disease (ESRD) necessitating treatments such as dialysis or kidney transplantation.
IgA nephropathy (IgAN) is a common glomerular disease affecting individuals across the age spectrum. However, there are differences in the presentation and prognosis of IgAN between elderly and young adults. Elderly patients with IgAN tend to present with more severe kidney disturbances, worse baseline renal function, and a poorer prognosis compared to young adults. The Oxford classification contributes to the overall prognosis of IgAN in elderly patients by improving prognostic assessment, providing a better determinant of kidney survival, and combining histopathologic findings with clinical features. It offers a more comprehensive approach to understanding the disease course and predicting outcomes in elderly individuals with IgAN. Understanding these differences is a fundamental basis for pinpointing potential therapeutic targets to mitigate age-related renal pathology in IgAN patients.
Introduction: The role of vitamin D in metabolism, bone-mineral regulation, and anti-oxidation effect has drawn researchers’ attention toward its exact role in hemodialysis. Objectives: In this study, the effect of uric acid level reduction on serum 25-hydroxy vitamin D levels in hemodialysis patients was assessed. Patients and Methods: This study is a triple-blind clinical trial conducted on 81 hemodialysis patients suffering from asymptomatic hyperuricemia. Serum uric acid levels were assessed at the start of the study. Then patients were divided randomly into two groups of intervention and control. The intervention group received 100 mg of allopurinol tablets daily for two months. The control group received placebo tablets for the same duration. At the end of the study, 25-hydroxyvitamin D and uric acid levels were assessed. Data were analyzed using SPSS software and chi-square, independent t test, Mann–Whitney U, and Spearman’s rank correlation tests. Results: In our study, two groups of control and intervention were similar in terms of patients’ demographic and hemodialysis characteristics. After the intervention, compared to the control group, the serum uric acid levels were significantly lower in the intervention group, while the level of 25-hydroxyvitamin D showed no significant difference between the two groups. Conclusion: In this study, no significant effect of uric acid lowering therapy with vitamin D elevation in hemodialysis patients was detected. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT2015041721803N1; https:// en.irct.ir/trial/18996, ethical code#IR.SKUMS.1395.231).
Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possible side effects. Recent studies present promising results of the new targeted-release formulation of budesonide that delivers the drug to the distal ileum to reduce side effects for patients with IgA nephropathy. In this paper, we highlighted the potential benefits of budesonide as a treatment option for IgA nephropathy and the need for additional studies to confirm its effectiveness. The lack of alternative treatments to prevent renal deterioration without other systemic side effects motivated us to gather relevant information to fill this gap. In this brief overview, we have reviewed some of the most recently published studies regarding how budesonide protects against IgA nephropathy. Studies reveal that budesonide might significantly decrease proteinuria, hematuria, and creatinine level while maintaining normal renal function. Though, a limited number of trials have been established to date, and further investigations are needed to confirm the benefit of the new targeted-release budesonide in treating IgA nephropathy.